Axsome Therapeutics Inc (AXSM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.45B
Last updated: Nov 17, 2026 at 11:05 AM ET
Axsome Therapeutics Inc (AXSM) Stock Forecast
Analysts expect Axsome Therapeutics (AXSM) to earn -$2.53 per share in the fiscal year ending Dec 31, 2026, on revenue of $952.18M. Of 22 analysts, 21 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $3.38.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 22 ratings average 1.91, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 95% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 13.6% |
| Buy | 18 | 81.8% |
| Hold | 1 | 4.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 22
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 52.3%.
- Fiscal year ending Dec 31, 2026
- -$2.53
- EPS consensus, revenue $952.18M
- Fiscal year ending Dec 31, 2027
- $3.38
- EPS consensus, revenue $1.45B
- Next report
- Feb 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.53 | -$3.33 to -$0.68 | 13 | $952.18M | $928.10M to $996.29M | 21 |
| Dec 31, 2027 | $3.38 | $0.93 to $7.25 | 13 | $1.45B | $1.31B to $1.74B | 21 |
Quarterly Estimates
The EPS consensus rises from -$0.01 for the quarter ending Dec 31, 2026 to $0.03 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.01 | -$0.53 to $0.67 | 24 | $291.88M | $254.50M to $343.35M | 23 |
| Mar 31, 2027 | $0.03 | -$0.21 to $0.27 | 2 | $297.49M | $277.20M to $335.47M | 7 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 5 upward and 6 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 4 | 6 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
The EPS consensus for the fiscal year ending Dec 31, 2026 is where it was 90 days ago.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.53 | -$2.43 | -$2.77 | -$2.64 | -$2.53 | N/A |
| Fiscal year ending Dec 31, 2027 | $3.38 | $3.69 | $4.66 | $5.03 | $5.05 | -33.1% |
| Quarter ending Mar 31, 2027 | $0.03 | -$0.34 | $0.16 | $0.12 | $0.30 | -89.9% |
Frequently Asked Questions About AXSM
What is the AXSM stock forecast?
Consensus analyst estimates put Axsome Therapeutics's EPS at -$2.53 for the fiscal year ending Dec 31, 2026, on revenue of $952.18M. The consensus rating from 22 analysts is Buy.
How do analysts rate AXSM stock?
Of 22 analysts covering Axsome Therapeutics, 3 rate it Strong Buy, 18 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from AXSM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.53, with estimates from -$3.33 to -$0.68 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.38, with estimates from $0.93 to $7.25 from 13 analysts.
What revenue do analysts expect from Axsome Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $952.18M, with estimates from $928.10M to $996.29M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.45B, with estimates from $1.31B to $1.74B.
How many analysts cover AXSM?
22 analysts rate Axsome Therapeutics stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
AXSM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors